Oric Pharmaceuticals, Inc. — Director's Dealing 2022

Jul 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2022-07-20

Reporting Person: Piscitelli Dominic (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-20	Stock Option (right to buy)	$6.44	D	207500	Disposed	2029-09-10	Common Stock (207500)	Direct
2022-07-20	Stock Option (right to buy)	$16.00	D	86250	Disposed	2030-04-22	Common Stock (86250)	Direct
2022-07-20	Stock Option (right to buy)	$29.83	D	90000	Disposed	2031-01-31	Common Stock (90000)	Direct
2022-07-20	Stock Option (right to buy)	$9.48	D	108750	Disposed	2032-01-31	Common Stock (108750)	Direct
2022-07-20	Stock Option (right to buy)	$4.36	A	207500	Acquired	2032-07-19	Common Stock (207500)	Direct
2022-07-20	Stock Option (right to buy)	$4.36	A	86250	Acquired	2032-07-19	Common Stock (86250)	Direct
2022-07-20	Stock Option (right to buy)	$4.36	A	90000	Acquired	2032-07-19	Common Stock (90000)	Direct
2022-07-20	Stock Option (right to buy)	$4.36	A	108750	Acquired	2032-07-19	Common Stock (108750)	Direct

Footnotes

F1: Twenty five percent (25%) of the shares subject to the option vested on September 10, 2020, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter.

F2: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share.

F3: Twenty five percent (25%) of the shares subject to the option vested on April 23, 2021, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter.

F4: Twenty five percent (25%) of the shares subject to the option vested on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested each month thereafter.

F5: Twenty five percent (25%) of the shares subject to the option would have vested on February 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option would have vested each month thereafter.

F6: One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter.

F7: Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.